Evidence map›Paper›PMID 37439357›Full record

ArticleHaematologica2023

Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study.

Arleigh McCurdy, Hsien Seow, Gregory P Pond, Anastasia Gayowsky, Rajshekhar Chakraborty, Alissa Visram, Rayan Kaedbey, Anita D'Souza, Ghulam Rehman Mohyuddin, Tanya M Wildes and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Perioperative considerations for patients with multiple myeloma.European journal of anaesthesiology and intensive care · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Arleigh McCurdyThe Ottawa Hospital Research Institute, Ottawa, ON. amccurdy@toh.ca.
Hsien SeowDepartment of Oncology, McMaster University, Hamilton, ON.
Gregory P PondDepartment of Oncology, McMaster University, Hamilton, ON.
Anastasia GayowskyICES McMaster, McMaster University, Hamilton, ON, Ontario.
Rajshekhar ChakrabortyColumbia University, New York, NY.
Alissa VisramThe Ottawa Hospital Research Institute, Ottawa, ON.
Rayan KaedbeyDepartment of Medicine, Jewish General Hospital, Montreal, QC.
Anita D'SouzaDivision of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI.
Ghulam Rehman MohyuddinDepartment of Hematology, Huntsman Cancer Institute, Salt Lake City, UT.
Tanya M WildesDivision of Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE.
Rafael FonsecaDivision of Hematology/Oncology, Mayo Clinic, Phoenix, AZ.
Hira MianDepartment of Oncology, McMaster University, Hamilton, ON.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Survival has improved in patients diagnosed with multiple myeloma (MM) over the last two decades; however, there remains a paucity of data on the causes of death in MM patients and whether causes of death change during the disease trajectory. We conducted a retrospective population-based study to evaluate the rates of MM-specific versus non-MM cause of death and to identify factors associated with cause-specific death in MM patients, stratified into autologous stem cell transplant (ASCT) and non-ASCT cohorts. A total of 6,677 patients were included, 2,576 in the ASCT group and 4,010 in the non-ASCT group. Eight hundred and seventy-three (34%) ASCT patients and 2,787 (68%) non-ASCT patients died during the follow-up period. MM was the most frequent causes of death, causing 74% of deaths in the ASCT group and 67% in the non-ASCT group. Other cancers were the second leading causes of death, followed by cardiac and infectious diseases. Multivariable analysis demonstrated that a more recent year of diagnosis and novel agent use within 1 year of diagnosis were associated with a decreased risk of MM-specific death, whereas a history of previous non-MM cancer, older age, and the presence of CRAB criteria at diagnosis increased the risk of non-MM death. Our data suggests that despite improvement in MM outcomes in recent years, MM remains the greatest threat to overall survival for patients. Further advances in the development of effective MM therapeutic agents in both ASCT and non-ASCT populations and patient access to them is needed to improve outcomes.

Indexed as

Hematopoietic Stem Cell TransplantationMultiple MyelomaHumansRetrospective StudiesStem Cell TransplantationTransplantation, Autologous

Identifiers

PMID37439357
PMCPMC10690919

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.